课题基金基金详情
芪苓温肾消囊方调控胆汁酸/IL22激活STAT3/AMPK通路治疗PCOS的分子机制研究
结题报告
批准号:
82004404
项目类别:
青年科学基金项目
资助金额:
24.0 万元
负责人:
常惠
依托单位:
学科分类:
中医妇科学
结题年份:
2023
批准年份:
2020
项目状态:
已结题
项目参与者:
常惠
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
PCOS是复杂的生殖内分泌疾病,以高雄激素血症、IR和卵巢功能障碍为主要临床表现,目前尚无有效治疗措施。本团队前期临床证明芪苓温肾消囊方治疗PCOS确有疗效,代谢组研究证明PCOS存在胆汁酸异常。本项目以IVF-ET痰湿型PCOS为研究对象,利用靶向代谢组学整合Western-Blot技术,通过靶向分析表征给予芪苓温肾消囊方后患者血清和卵泡液中胆汁酸代谢改变,分析血清和颗粒细胞IL-22等水平和mRNA表达,以及炎症因子和STAT3/AMPK mRNA和相关蛋白的表达,阐明PCOS胆汁酸-白介素异常的发病通路及代谢机制。验证芪苓温肾消囊方通过调控胆汁酸代谢调节IL-22表达,激活STAT3/AMPK通路,抑制颗粒细胞炎症因子产生,治疗PCOS的假说。本研究首次基于胆汁酸-白介素-STAT3/MAPK通路,从整体、细胞、分子,多层次、多角度分析中药复方作用机制,为临床治疗PCOS提供新思路。
英文摘要
PCOS is a complex reproductive endocrine disease, with hyperandrogenemia, IR and ovarian dysfunction as the main clinical manifestations, while there is no effective treatment measures currently. Our team has proved that Qiling Wenshen Xiaonang Formula was an effective prescription for the treatment of PCOS. Metabolome study proved that PCOS had abnormal bile acid. In this project, phlegm-dampened PCOS patients treated by IVF-ET were taken as the research objects.Using targeted metabonomics integrated Western Blot technique and targeted analysis of metabolic changes of bile acid in serum and follicular fluid of patients treated with Qiling Wenshen Xiaonang Formula, IL - 22 level in serum and cell, mRNA expression, the expression of inflammatory factor, STAT3 / AMPK mRNA and related proteins were analyzed to clarify pathological and metabolic mechanisms of PCOS with bile acid-interleukin-abnormality. It aims to verify the hypothesis of treating PCOS by regulating the expression of IL - 22, activating the STAT3/AMPK pathway, inhibiting the production of granulosa cell inflammatory factors, and regulating bile acid metabolism by Qiling Wenshen Xiaonang Formula. It is the first time to analyze the mechanism of Qiling Wenshen Xiaonang Formula from a holistic, cellular, molecular, multi-level and multi-layer perspective, based on the bile acid-interleukin-STAT3 /MAPK pathway, in order to provide a new idea for the clinical treatment of PCOS.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.1080/09513590.2023.2263085
发表时间:2023-12-14
期刊:GYNECOLOGICAL ENDOCRINOLOGY
影响因子:2
作者:Chang,Hui;Ge,Hang;Wu,Xiaoke
通讯作者:Wu,Xiaoke
DOI:10.3389/fendo.2023.1237260
发表时间:2023
期刊:Frontiers in endocrinology
影响因子:5.2
作者:
通讯作者:
DOI:--
发表时间:2023
期刊:中华中医药杂志
影响因子:--
作者:刘理凤;常惠;万天恩;张婉玉;马呈呈;韩延华;吴效科
通讯作者:吴效科
DOI:--
发表时间:2021
期刊:中国中西医结合杂志
影响因子:--
作者:常惠;朱梦一;付新;沈文娟;张跃辉;韩延华;吴效科.
通讯作者:吴效科.
DOI:--
发表时间:2024
期刊:中国中西医结合杂志
影响因子:--
作者:常惠;王俐榕;冀凡;马呈呈;万天恩
通讯作者:万天恩
国内基金
海外基金